Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2021, with a specific reporting date of September 22, 2021. The document serves as a transaction notification regarding share allocations for Non-Executive Directors under the company's share allocation arrangements for the service period of July 1, 2021, to September 30, 2021.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions involving the acquisition of notional shares by Persons Discharging Managerial Responsibilities (PDMRs).
| Instrument | Price | Total Volume (Shares/ADSs) | Transaction Date |
|---|---|---|---|
| Ordinary Shares (GBP) | £13.94 | 4,999.105 | 2021-09-20 |
| American Depositary Shares (USD) | $39.09 | 3,371.115 | 2021-09-20 |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. The only reported activity is the routine acquisition of notional shares by Non-Executive Directors as compensation for their service.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a statutory disclosure of director share transactions.
Investor Verification Points
- Verify the total number of Ordinary Shares and ADSs allocated to Non-Executive Directors for the Q3 2021 period.
- Confirm the transaction price of £13.94 per Ordinary Share and $39.09 per ADS against market prices on September 20, 2021.
- Review the specific share allocation arrangements for Non-Executive Directors to understand the vesting or holding conditions associated with these notional acquisitions.